-
Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy
Veldkamp, S. R., Reugebrink, M., Evers, S. W., Moreau, T. R. J., Bondet, V., Armbrust, W., van den Berg, J. M., Hissink Muller, P. C. E., Kamphuis, S., Schatorjé, E., Delemarre, E. M., van der Kooi, A. J., Bader-Meunier, B., Duffy, D., Rodero, M. P., Raaphorst, J., van Royen-Kerkhof, A., Jansen, M. H. A. & van Wijk, F., 1 Sept 2025, In: Nature Clinical Practice Rheumatology. 64, 9, p. 5132-5141 10 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Type i interferon biomarker in idiopathic inflammatory myopathies: Associations of Siglec-1 with disease activity and treatment response
Kamperman, R. G., Veldkamp, S. R., Evers, S. W., Lim, J., van Schaik, I., van Royen-Kerkhof, A., van Wijk, F., van der Kooi, A. J., Jansen, M. & Raaphorst, J., 1 May 2025, In: Nature Clinical Practice Rheumatology. 64, 5, p. 2979-2986 8 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial
Kamperman, R. G., Bogaards, J. A., Evers, S. W., Walter, H. A. W., de Visser, M., de Borgie, C., Colen - de Koning, J. C. A., Verhamme, C., Maas, M., Eftimov, F., van Schaik, I. N., van der Kooi, A. J. & Raaphorst, J., 10 Jul 2023, In: BMJ open. 13, 7, e067435.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
